Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors Authors
نویسندگان
چکیده
Affiliations Department of Medical Oncology and Center for Cancer Genome Discovery, DanaFarber Cancer Institute, Boston, MA, USA Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA The Broad Institute, Cambridge, MA, USA Division of Cancer Therapeutics, Institute of Cancer Research, London, SW7 3RP, United Kingdom Corresponding author Levi A. Garraway, MD, PhD, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, D1542, Boston, MA 02215, USA Phone: 617-632-6689 Fax: 617-582-7880 Email: [email protected] Financial support This study was supported by grants to L.A. Garraway from the National Cancer Institute (5P50CA127003-05) STARR Cancer Consortium (I4-A448), the NIH New Innovator Award (DP2OD002750) and the Melanoma Research Alliance. Conflicts of Interest Dr. Garraway is a consultant to Novartis, Millenium/Takeda, and Boehringer Ingelheim, and a recipient of a grant from Novartis.
منابع مشابه
Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
RAF and MEK inhibitors are effective in BRAF-mutant melanoma but not in BRAF-mutant colorectal cancer. To gain additional insights into this difference, we performed a genome-scale pooled shRNA enhancer screen in a BRAF-mutant, RAF inhibitor-resistant colorectal cancer cell line exposed to the selective RAF inhibitor PLX4720. We identified multiple genes along the receptor tyrosine kinase (RTK)...
متن کاملERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.
The use of targeted therapeutics directed against BRAF(V600)-mutant metastatic melanoma improves progression-free survival in many patients; however, acquired drug resistance remains a major medical challenge. By far, the most common clinical resistance mechanism involves reactivation of the MAPK (RAF/MEK/ERK) pathway by a variety of mechanisms. Thus, targeting ERK itself has emerged as an attr...
متن کاملMAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MAP-ERK kinase (MEK)1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with dabrafenib monotherapy. Mechanisms of clinical resistance to combined RAF/MEK inhibition are unknown. We performed whole-exome sequencing (WES) and whole-transcript...
متن کاملERK inhibition overcomes acquired resistance to MEK inhibitors.
The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several allosteric mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, aimed at treating tumors with RAS/RAF pathway alterations, are in clinical development. However, acquired resistance to these inhibitors has be...
متن کاملPreclinical Development ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several allosteric mitogen-activated protein/ extracellular signal–regulated kinase (MEK) inhibitors, aimed at treating tumors with RAS/RAF pathway alterations, are in clinical development. However, acquired resistance to these inhibitors has b...
متن کامل